HRP20190093T1 - Primarni karboksamidi kao inhibitori btk - Google Patents

Primarni karboksamidi kao inhibitori btk

Info

Publication number
HRP20190093T1
HRP20190093T1 HRP20190093TT HRP20190093T HRP20190093T1 HR P20190093 T1 HRP20190093 T1 HR P20190093T1 HR P20190093T T HRP20190093T T HR P20190093TT HR P20190093 T HRP20190093 T HR P20190093T HR P20190093 T1 HRP20190093 T1 HR P20190093T1
Authority
HR
Croatia
Prior art keywords
btk inhibitors
primary carboxamides
carboxamides
primary
btk
Prior art date
Application number
HRP20190093TT
Other languages
English (en)
Croatian (hr)
Inventor
Dominique Bonafoux
Heather M. Davis
Kristine E. Frank
Michael M. Friedman
J. Martin Herold
Michael Z. Hoemann
Raymond Huntley
Augustine Osuma
George Sheppard
Gagandeep K. SOMAL
Jennifer Van Camp
Stacy A. Van Epps
Anil Vasudevan
Grier A. Wallace
Lu Wang
Zhi Wang
Noel S. Wilson
Xiangdong Xu
Original Assignee
Abbvie Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc. filed Critical Abbvie Inc.
Publication of HRP20190093T1 publication Critical patent/HRP20190093T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
HRP20190093TT 2013-06-26 2014-06-26 Primarni karboksamidi kao inhibitori btk HRP20190093T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361839729P 2013-06-26 2013-06-26
US201361897577P 2013-10-30 2013-10-30
EP14817453.5A EP3013337B1 (en) 2013-06-26 2014-06-26 Primary carboxamides as btk inhibitors
PCT/US2014/044247 WO2014210255A1 (en) 2013-06-26 2014-06-26 Primary carboxamides as btk inhibitors

Publications (1)

Publication Number Publication Date
HRP20190093T1 true HRP20190093T1 (hr) 2019-02-22

Family

ID=52116191

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190093TT HRP20190093T1 (hr) 2013-06-26 2014-06-26 Primarni karboksamidi kao inhibitori btk

Country Status (28)

Country Link
US (4) US9567339B2 (enExample)
EP (3) EP4008328A1 (enExample)
JP (3) JP6509838B2 (enExample)
KR (1) KR102273997B1 (enExample)
CN (1) CN105530932B (enExample)
AU (3) AU2014302365B2 (enExample)
BR (1) BR112015032330B1 (enExample)
CA (1) CA2916298C (enExample)
CY (1) CY1121146T1 (enExample)
DK (1) DK3013337T3 (enExample)
ES (1) ES2708998T3 (enExample)
HR (1) HRP20190093T1 (enExample)
HU (1) HUE040645T2 (enExample)
IL (2) IL243332B (enExample)
LT (1) LT3013337T (enExample)
ME (1) ME03307B (enExample)
MX (1) MX355943B (enExample)
NZ (1) NZ754039A (enExample)
PL (1) PL3013337T3 (enExample)
PT (1) PT3013337T (enExample)
RS (1) RS58273B1 (enExample)
RU (1) RU2708395C2 (enExample)
SG (2) SG11201510503UA (enExample)
SI (1) SI3013337T1 (enExample)
TW (1) TWI642657B (enExample)
UY (1) UY35630A (enExample)
WO (1) WO2014210255A1 (enExample)
ZA (1) ZA201509012B (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
MX355943B (es) * 2013-06-26 2018-05-07 Abbvie Inc Carboxamidas primarias como inhibidores de btk.
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
CN104341388B (zh) 2013-10-16 2017-03-22 北京诺诚健华医药科技有限公司 芳香族酰胺类衍生物、其制备方法及其在医药上的应用
PT3461821T (pt) * 2014-10-24 2020-08-05 Bristol Myers Squibb Co Compostos de indol carboxamida úteis como inibidores de quinase
AR104259A1 (es) * 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
US10253041B2 (en) * 2015-07-27 2019-04-09 Eli Lilly And Company 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds and their use as mutant IDH1 inhibitors
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
NZ741294A (en) * 2015-11-17 2023-07-28 Merck Patent Gmbh Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity
AU2016358100B2 (en) 2015-11-19 2021-05-27 Incyte Corporation Heterocyclic compounds as immunomodulators
SG11201804170RA (en) 2015-12-17 2018-06-28 Merck Patent Gmbh Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
TW201726623A (zh) 2015-12-17 2017-08-01 英塞特公司 作為免疫調節劑之雜環化合物
TWI850624B (zh) 2015-12-22 2024-08-01 美商英塞特公司 作為免疫調節劑之雜環化合物
TW201808950A (zh) 2016-05-06 2018-03-16 英塞特公司 作為免疫調節劑之雜環化合物
US20170335530A1 (en) * 2016-05-23 2017-11-23 Fatu K. Kofa Pet waste vacuum and disposal device and method
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
CN105924840A (zh) * 2016-06-01 2016-09-07 扬州兰都塑料科技有限公司 一种阻燃电力电缆
CN106083707B (zh) * 2016-06-01 2018-10-26 温州大学 一种非对称杂芳基硫醚的合成方法
CN105837993A (zh) * 2016-06-01 2016-08-10 扬州兰都塑料科技有限公司 一种阻燃电力电缆用阻燃剂
CN105884673B (zh) * 2016-06-03 2018-05-11 温州大学 一种吲哚衍生物的合成方法
DK3472167T3 (da) 2016-06-20 2022-09-05 Incyte Corp Heterocykliske forbindelser som immunomodulatorer
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3497094B1 (en) 2016-08-08 2023-02-15 Merck Patent GmbH Tlr7/8 antagonists and uses thereof
EP3504198B1 (en) 2016-08-29 2023-01-25 Incyte Corporation Heterocyclic compounds as immunomodulators
PT3507282T (pt) * 2016-09-02 2020-12-23 Bristol Myers Squibb Co Processo para a preparação de compostos de indol carboxamida
US10906905B2 (en) 2016-10-14 2021-02-02 Jiangsu Hengrui Medicine Co., Ltd. Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof
JP2020510624A (ja) 2016-12-12 2020-04-09 マルチビア インコーポレイテッド がんおよび感染性疾患の治療および予防のための、ウイルス遺伝子治療および免疫チェックポイント阻害剤を含む方法および組成物
IL295660A (en) 2016-12-22 2022-10-01 Incyte Corp Benzooxazole derivatives as immunomodulators
ES2929193T3 (es) 2016-12-22 2022-11-25 Incyte Corp Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de la internalización de PD-L1
EP3558973B1 (en) 2016-12-22 2021-09-15 Incyte Corporation Pyridine derivatives as immunomodulators
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
EP3558963B1 (en) 2016-12-22 2022-03-23 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
JP2020505395A (ja) * 2017-01-26 2020-02-20 アラクセス ファーマ エルエルシー 縮合ｎ−複素環式化合物およびその使用方法
CN106928201B (zh) * 2017-02-22 2019-08-23 江汉大学 合成2-乙烯基吲哚衍生物的方法
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
CN107098845A (zh) * 2017-07-06 2017-08-29 贵州大学 一种5‑氰基‑6‑硝基吲哚的制备工艺
CN107721988A (zh) * 2017-10-31 2018-02-23 无锡福祈制药有限公司 具有抗炎活性的异吲哚‑1‑酮类化合物
MX2020008627A (es) 2018-02-19 2020-09-21 Guangzhou Lupeng Pharmaceutical Company Ltd Inhibidores de btk y mutantes de los mismos.
RS64055B1 (sr) 2018-03-30 2023-04-28 Incyte Corp Heterociklična jedinjenja kao imunomodulatori
EP4219492B1 (en) 2018-05-11 2024-11-27 Incyte Corporation Heterocyclic compounds as immunomodulators
CA3107168A1 (en) 2018-08-01 2020-02-06 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
JP7665593B2 (ja) 2019-08-09 2025-04-21 インサイト・コーポレイション Ｐｄ－１／ｐｄ－ｌ１阻害剤の塩
EP4037773A1 (en) 2019-09-30 2022-08-10 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
BR112022009031A2 (pt) 2019-11-11 2022-10-11 Incyte Corp Sais e formas cristalinas de um inibidor de pd-1/pd-l1
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4149459A4 (en) * 2020-05-12 2024-05-22 PMV Pharmaceuticals, Inc. METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION
AU2021283916A1 (en) * 2020-06-02 2023-01-05 Vidya Therapeutics, Inc. Kinase inhibitors
WO2021255091A1 (en) 2020-06-19 2021-12-23 Bayer Aktiengesellschaft 1,3,4-oxadiazoles and their derivatives as fungicides
CN116096414A (zh) 2020-08-04 2023-05-09 诺华股份有限公司 Cll的治疗
PE20230782A1 (es) 2020-09-30 2023-05-09 Astrazeneca Ab Compuestos y su uso en el tratamiento del cancer
WO2022094172A2 (en) * 2020-10-30 2022-05-05 Newave Pharmaceutical Inc. Inhibitors of btk
EP4240739A1 (en) 2020-11-06 2023-09-13 Incyte Corporation Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
CN117015528A (zh) * 2021-01-12 2023-11-07 Gb005股份有限公司 作为激酶抑制剂的吲哚衍生物
CN114853723B (zh) * 2021-02-03 2023-11-24 药雅科技(上海)有限公司 吲哚类化合物btk抑制剂的制备及其应用
US20240190864A1 (en) * 2021-02-03 2024-06-13 Ya Therapeutics Inc Bruton's Tyrosine Kinase (BTK) INHIBITOR AND APPLICATION THEREOF
CN114853752B (zh) * 2021-02-03 2023-08-22 药雅科技(上海)有限公司 Btk抑制剂吡啶并杂环类化合物的制备及其应用
CN114957241B (zh) * 2021-02-23 2023-08-22 药雅科技(上海)有限公司 杂环类化合物作为激酶抑制剂的制备及其应用
CN114957242B (zh) * 2021-02-23 2023-08-22 药雅科技(上海)有限公司 吡啶并杂环类化合物作为激酶抑制剂的制备及其应用
CN116348453B (zh) * 2021-04-25 2025-07-04 烨辉医药科技(上海)有限公司 杂芳族甲酰胺化合物及其用途
CN115521313B (zh) * 2021-06-24 2023-11-03 山东大学 一种降解btk蛋白的化合物及其制备方法和应用
EP4469043A4 (en) 2022-01-27 2026-02-25 Pmv Pharmaceuticals Inc DEUTERATED COMPOUNDS TO RESTORE MUTANT P53 FUNCTION
WO2023227080A1 (zh) * 2022-05-25 2023-11-30 百极弘烨(南通)医药科技有限公司 一种protac化合物、含其的药物组合物及其制备方法和应用
WO2023250431A2 (en) * 2022-06-22 2023-12-28 Children's Hospital Medical Center Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
AU2023361174A1 (en) * 2022-10-12 2025-05-01 Maze Therapeutics, Inc. Inhibitors of solute carrier family 6a member 19 (slc6a19) and methods of use thereof
KR102827002B1 (ko) * 2023-06-28 2025-06-30 국립순천대학교산학협력단 신규한 마리노바자난 화합물 및 이를 포함하는 암 전이 및 침윤 억제, 또는 암 치료용 조성물

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4025510A (en) * 1975-12-01 1977-05-24 E. I. Du Pont De Nemours And Company 2,4-Diaryl[1,3,4H]thiadiazines fused to quinoxalines
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DE10022925A1 (de) * 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
US20040235867A1 (en) * 2001-07-24 2004-11-25 Bilodeau Mark T. Tyrosine kinase inhibitors
JP2006512313A (ja) * 2002-10-31 2006-04-13 アムジェン インコーポレイテッド 抗炎症剤
CA2534127A1 (en) 2003-07-31 2005-02-10 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzothiophene compounds and uses thereof
GB0400895D0 (en) * 2004-01-15 2004-02-18 Smithkline Beecham Corp Chemical compounds
KR100796965B1 (ko) * 2004-05-04 2008-01-22 에프. 호프만-라 로슈 아게 Ｉｋｋ 저해제로서의 티에노피리딘
BRPI0511874A (pt) 2004-06-09 2008-01-15 Glaxo Group Ltd derivados da pirrolopiridina
TW200626142A (en) * 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
MX2007012448A (es) 2005-04-06 2007-10-19 Astrazeneca Ab Heterociclos sustituidos y su uso como inhibidores de chk1, pdk1 y pak.
CN101189243A (zh) * 2005-04-06 2008-05-28 阿斯利康(瑞典)有限公司 取代的杂环及其作为chk1、pdk1和pak抑制剂的应用
US8063071B2 (en) * 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
UA99699C2 (ru) * 2005-06-30 2012-09-25 Смитклайн Бичам Корпорейшн Производные индолкарбоксамида и фармацевтическая композиция, которая их содержит
CA2647545C (en) 2006-04-03 2016-02-23 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors
PE20081889A1 (es) * 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
CA2684240A1 (en) * 2007-04-16 2008-10-30 Serenex, Inc. Tetrahydroindole and tetrahydroindazole derivatives
EP2144630A2 (en) * 2007-04-27 2010-01-20 AstraZeneca AB Chk1 inhibitors with b cell depleting antibodies for the treatment of hematologic malignancies
EP2152318A4 (en) * 2007-06-01 2011-12-07 Abbott Biotech Ltd COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE
CN101481380B (zh) * 2008-01-08 2012-10-17 浙江医药股份有限公司新昌制药厂 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途
AR070317A1 (es) 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
BRPI0922565A2 (pt) 2008-12-19 2015-12-15 Bristol Myers Squibb Co compostos de carbazol carboxamida úteis como inibidores de cinase
CA2771822C (en) 2009-09-04 2020-08-11 Daniel A. Erlanson Bruton's tyrosine kinase inhibitors
WO2011075699A2 (en) 2009-12-18 2011-06-23 Sunovion Pharmaceuticals Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
US20110212461A1 (en) 2010-02-26 2011-09-01 Hans Marcus Ludwig Bitter Prediction of cardiotoxicity
KR20130083386A (ko) 2010-05-20 2013-07-22 에프. 호프만-라 로슈 아게 피롤로[2,3-ｂ]피라진-7-카복스아마이드 유도체 및 ＪＡＫ 및 ＳＹＫ 억제제로서의 그의 용도
EP2582668B1 (en) 2010-06-16 2016-01-13 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
WO2012009649A1 (en) 2010-07-16 2012-01-19 Anderson Gaweco Mif inhibitors and their uses
RU2013114352A (ru) 2010-09-15 2014-10-20 Ф. Хоффманн-Ля Рош Аг Азабензотиазолы, композиции и способы применения
FR2969151B1 (fr) * 2010-12-17 2016-11-04 Oreal Derives du 4-amino et leur utilisation pour la coloration d'oxydation des fibres keratiniques.
US9133164B2 (en) 2011-04-13 2015-09-15 Innov88 Llc MIF inhibitors and their uses
EP2561759A1 (en) * 2011-08-26 2013-02-27 Bayer Cropscience AG Fluoroalkyl-substituted 2-amidobenzimidazoles and their effect on plant growth
WO2013148603A1 (en) 2012-03-27 2013-10-03 Takeda Pharmaceutical Company Limited Cinnoline derivatives as as btk inhibitors
MX355943B (es) * 2013-06-26 2018-05-07 Abbvie Inc Carboxamidas primarias como inhibidores de btk.

Also Published As

Publication number Publication date
AU2014302365B2 (en) 2018-11-15
EP3013337B1 (en) 2018-10-31
IL243332A0 (en) 2016-02-29
DK3013337T3 (en) 2019-02-25
RU2016102137A (ru) 2017-07-31
EP4008328A1 (en) 2022-06-08
TWI642657B (zh) 2018-12-01
RS58273B1 (sr) 2019-03-29
RU2016102137A3 (enExample) 2018-04-28
NZ754039A (en) 2021-06-25
RU2708395C2 (ru) 2019-12-06
SI3013337T1 (sl) 2019-02-28
AU2014302365A1 (en) 2015-12-24
EP3483167A1 (en) 2019-05-15
JP2019123740A (ja) 2019-07-25
HUE040645T2 (hu) 2019-03-28
ME03307B (me) 2019-10-20
IL267101A (en) 2019-08-29
LT3013337T (lt) 2019-01-10
US20210179556A1 (en) 2021-06-17
SG10201802444XA (en) 2018-05-30
UY35630A (es) 2015-01-30
IL243332B (en) 2019-06-30
BR112015032330B1 (pt) 2019-01-22
US20190284135A1 (en) 2019-09-19
WO2014210255A1 (en) 2014-12-31
CA2916298A1 (en) 2014-12-31
JP2021001212A (ja) 2021-01-07
AU2019200901A1 (en) 2019-02-28
PL3013337T3 (pl) 2019-06-28
CA2916298C (en) 2021-10-12
KR102273997B1 (ko) 2021-07-08
NZ714797A (en) 2021-06-25
MX355943B (es) 2018-05-07
CY1121146T1 (el) 2020-05-29
JP6509838B2 (ja) 2019-05-08
CN105530932B (zh) 2019-09-27
HK1224202A1 (en) 2017-08-18
ZA201509012B (en) 2020-05-27
MX2015017973A (es) 2016-05-10
US20150005279A1 (en) 2015-01-01
EP3013337A1 (en) 2016-05-04
ES2708998T3 (es) 2019-04-12
US9567339B2 (en) 2017-02-14
TW201514145A (zh) 2015-04-16
US20170174624A1 (en) 2017-06-22
BR112015032330A2 (pt) 2017-08-22
PT3013337T (pt) 2019-02-05
EP3013337A4 (en) 2016-12-28
JP2016523911A (ja) 2016-08-12
CN105530932A (zh) 2016-04-27
KR20160025580A (ko) 2016-03-08
JP6770127B2 (ja) 2020-10-14
AU2021201463A1 (en) 2021-03-25
SG11201510503UA (en) 2016-01-28

Similar Documents

Publication Publication Date Title
IL267101A (en) Primary carboxamides as btk inhibitors
IL279682A (en) Benzoquinolone compounds as VMAT2 inhibitors
EP3082809A4 (en) Btk inhibitors
EP3008633A4 (en) QUICK GROUPING OF TIME SERIES
GB201304526D0 (en) New compounds
ZA201506156B (en) Novel inhibitors
GB201518344D0 (en) No details present
PT2943561T (pt) Fotobiorreator
EP3082811A4 (en) Btk inhibitors
IL244617A0 (en) Benzoquinolone compounds as vmat2 inhibitors
GB201304527D0 (en) New compounds
IL240763A0 (en) The halopyrazoles as thrombin inhibitors
GB201322992D0 (en) New Process
GB201310928D0 (en) New Processes
GB201301346D0 (en) Well completion
GB201317756D0 (en) New process
GB201313211D0 (en) New process
GB201305503D0 (en) Inhibitor
GB201318565D0 (en) New processes
GB201300961D0 (en) New processes
GB201305945D0 (en) New compounds
GB201304773D0 (en) New compounds
GB201304777D0 (en) New compounds
GB201304780D0 (en) New compounds
GB201304782D0 (en) New compounds